Actos Litigation Continues

Litigation involving the drug Actos (Pioglitazone) is continuing in the class actions posture following a verdict in a bellweather case in excess of $9 billion dollars.

The manufacturer of Actos,Takeda Pharmaceutical Co., made more than $16 billion before Actos went generic in 2012.  While internal records show that Takeda knew about a link between Actos and bladder cancer as early as 2004, the company did not alert U.S. regulators for another seven years.

Pharmaceutical companies place the public health at risk when they rush drugs like Actos to the market and then fail to disclose known risks that would allow patients and doctors to make informed decisions about proper care.  In doing so, these companies place profit over people, and their actions can have serious consequences.

If you are among the millions of Americans who took Actos, and then you developed bladder cancer, you may have a potential claim.  There are currently more than 6,000 individuals involved the pending class action.

If you have questions about Actos, or questions about whether you may have a claim, contact the attorneys at Bryan & Terrill, 918-935-2777.